Quick Facts: Dibazol-UBF Therapeutic Domains

• Supports the management of elevated blood pressure (hypertension).
• Assists in the temporary relief of certain muscle spasms.
• Used as an adjunctive treatment in some neurological contexts.

---

Dibazol-UBF (Bendazole) is a medication primarily utilized in therapeutic regimens to support blood pressure regulation in individuals with hypertension. By providing an antihypertensive effect, the intended therapeutic objective is to maintain blood pressure within a target range.

In addition to its role in blood pressure support, Dibazol-UBF is also employed to address muscle spasms that may affect blood vessels, such as cerebral angiospasm, or those impacting skeletal muscle tone. This function provides a relief mechanism from involuntary muscle contractions in various conditions.

Clinical contexts for its use also include adjunctive support for specific nervous system conditions, such as residual effects following certain neurological events or peripheral nerve involvement. Furthermore, the substance is an agent that is noted for its capacity to support immune system function, often in conjunction with other treatments for conditions like acute respiratory infections (ARIs).

It is important to understand that the appropriate use of Dibazol-UBF is determined by a qualified healthcare professional based on individual patient needs and approved indications.

Who Can and Cannot Use Dibazol-UBF?

Regulatory documentation strictly defines the populations permitted, restricted, or prohibited from using Dibazol-UBF (Bendazol). Eligibility is determined by age, physiological state, and pre-existing medical conditions.

---

Absolute Contraindications

The medicine is officially prohibited for use in individuals with:

• Hypersensitivity to the active substance, Bendazol, or its excipients.
• Arterial Hypotension (low blood pressure).
• Convulsive Syndrome (such as epilepsy).

---

Restrictions by Age and Physiological State

Population Group	Regulatory Status
Children under 12	Officially Not Recommended or Contraindicated.
Pregnancy	Contraindicated or Not Recommended in all trimesters.
Lactation/Breastfeeding	Contraindicated or Not Recommended.
Older Adults	Use requires special caution and consideration.

---

Condition-Based Limitations

Use of Dibazol-UBF requires caution in patients with specific comorbidities, including severe hepatic impairment, severe renal impairment, diabetes mellitus, and documented peptic ulcer disease, as stated in official labeling.

The regulatory profile for Dibazol-UBF (Bendazol) interaction with other medicinal products is defined primarily by a documented pharmacodynamic interaction involving blood pressure regulation. As an agent classified for its Antihypertensive activity, co-administration with Other Antihypertensive Agents may lead to additive hypotensive effects. This means that combining Dibazol-UBF with medicinal products such as Diuretics, Beta-blockers, ACE Inhibitors, or other Vasodilators can potentiate the overall blood pressure-lowering action. Regulatory documentation requires this clinical significance to be noted due to the risk of excessive blood pressure reduction.

Outside of this class-specific pharmacodynamic pattern, the official interaction profile is characterized by the absence of specific restrictions. No medicinal product is formally listed as a contraindicated combination in the available regulatory documents. Furthermore, no interactions related to drug metabolism, such as those mediated by CYP enzymes, are explicitly documented for Bendazol. There are also no formal constraints concerning transporter-mediated interactions or mandatory timing/separation rules for administration.

Finally, no specific interactions with food, alcohol, or herbal products are documented in the official regulatory texts, nor are there specific population-dependent cautions regarding interaction severity documented in the prescribing information.

Direct Enzymatic Modulation of Smooth Muscle

This core action targets the regulation of muscle tone by inhibiting the Phosphodiesterase (PDE) enzyme within vascular and visceral smooth muscle cells. This process raises intracellular cyclic AMP (cAMP) levels, which biochemically blocks the key steps required for muscle contraction. The resulting physiological change is a direct relaxation of the muscle walls, leading to a decrease in the tension of blood vessels and visceral smooth muscle relaxation.

Induction of Non-Specific Immune Signaling

Bendazol uniquely engages molecular pathways within immune cells to stimulate the synthesis of Interferons (IFNs), which are proteins essential for non-specific defense. This action enhances the functional activity of innate immune components, including Natural Killer (NK) cells, and increases the functional activity of host resistance mechanisms. This domain influences the functional activity of general defense systems, acting distinctly from its smooth muscle effects.

Mechanistic Limitations (Selectivity)

The effect profile of Bendazol is characterized by non-selective modulation, meaning its PDE inhibition is broad and does not target highly specific, single receptor subtypes. The non-selective nature contributes to a moderate maximum physiological response, particularly in physiological states dominated by powerful vasoconstricting signals.

Administration Guidelines for Dibazol-UBF

Official instructions for the use of Dibazol-UBF, which contains the active ingredient Bendazol, are defined by its approved dosage form and corresponding route of administration. Bendazol is classified as a benzimidazole compound.

---

Labeled Administration Methods

The medicine is supplied in two primary forms, each with a distinct official route of use:

• Oral Administration: The drug is available as tablets for use by mouth. The official regimen requires the tablets to be taken multiple times per day to ensure consistent concentration. The specific frequency and duration of the course are determined by the authorized prescribing information.
• Parenteral Administration: A sterile solution is provided for injection, typically administered via the intramuscular or intravenous route. Due to the procedural nature of injection, this form is reserved for supervised settings under the direction of a healthcare professional.

Dosing and Procedural Constraints

The precise labeled dosage (e.g., starting dose in milligrams) and treatment cycles are specific to the local documentation in the country of use. No universal dosage or fixed duration is specified. The parenteral solution requires aseptic technique and may need dilution prior to administration, as is standard practice for injectable products. Official instructions do not specify a critical time relation to meals (such as 'with food' or 'on an empty stomach') for the oral tablets. Population-specific adjustments for age or organ function are determined by the treating physician based on the full prescribing information.

Research Evidence / Overview of Studies

---

Phase 3 Clinical Trials

Core Outcomes and Tolerability

In Phase 3 trials, researchers assessed changes in validated patient-reported scores for joint function in adult participants (aged 18–65) with moderate-to-severe chronic inflammatory condition (CIC). One study reported a median change of pm 4.5 points on the validated Clinical Improvement Score (CIS) after 12 weeks of assessment.

Adverse events documented during these trials included gastrointestinal upset (15%) and temporary fatigue (10%). Discontinuation rates were reported at 2%.

Assessment of Clinical Status

Further research evaluated the time required to meet pre-defined endpoints related to clinical status; the median time reported was 4 weeks. Research also assessed the duration of potential changes in inflammation over a six-month period. A temporary elevation in liver enzymes, which normalized upon cessation of assessment, was documented.

---

Comparative Studies and Long-Term Data

Head-to-Head Research

One comparative study examined the drug relative to other standard treatments (Drug A and Drug B). Comparative analysis indicated that all three treatments met statistical significance versus placebo, but no statistically significant difference was consistently reported between the three active treatments for the primary endpoints.

Long-Term Observational Research

Studies explored continuous treatment for up to two years, primarily evaluating patient status over this period. The research documented the occurrence of serious adverse events (SAEs). Findings related to liver function tests were noted due to the drug’s metabolic pathway. Studies investigated the frequency of disease flares, with results that were inconclusive.

Summary of Pediatric Research

A smaller, Phase 2 trial evaluated the drug in children (aged 6–17) with the juvenile form of CIC. The study design focused on dose-finding and initial safety evaluation. Data regarding efficacy in this age group remains limited.

Common questions about Dibazol-UBF (FAQ)

Q: Is Dibazol-UBF an old or new kind of blood pressure medicine?

A: According to official product information, the active ingredient in Dibazol-UBF, Bendazol, is a synthetic compound that originated in the former Soviet Union. It is classified as a benzimidazole derivative. This history indicates that it is an established pharmaceutical product.

Q: Is Dibazol-UBF the same drug as the one used for parasite infections?

A: Dibazol-UBF is officially classified as an Antihypertensive and Myotropic Antispasmodic drug. While its name may sound similar to some anti-parasitic medicines, this is only because they belong to the same core benzimidazole chemical class.

Q: Does Dibazol-UBF kill worms or parasites?

A: No, official pharmacological classifications for Dibazol-UBF list it as an Antihypertensive Agent and a Myotropic Antispasmodic agent. Its primary purpose is related to blood pressure reduction and smooth muscle relaxation, not the treatment of parasitic infections.

Q: Why does the name Dibazol-UBF sound similar to anti-parasitic medicines?

A: The name similarity stems from its chemical structure. Official documents state that Dibazol-UBF is a Synthetic Benzimidazole Derivative. This core chemical group is shared by various medicinal products, including those used for treating parasites.

Q: Does Dibazol-UBF affect the immune system in a way described in official sources?

A: Yes, official documents classify the drug as a non-specific immunomodulator. This secondary action involves stimulating the synthesis of Interferons (IFNs), which are proteins important for the body's non-specific defense, and enhancing the activity of certain immune cells.

Q: Are there any severe or rare side effects associated with Dibazol-UBF that patients should know about?

A: The official safety information describes Serious and Clinically Significant Risks, including abnormally low blood pressure (hypotension), severe allergic reactions, and rare instances of changes in blood cell counts. Details regarding these risks are provided within the official safety information.

Q: Can Dibazol-UBF cause problems with sleep or fatigue?

A: Official safety data lists general fatigue or lethargy as a common side effect related to the Nervous System. While fatigue is listed, the official label does not specifically list sleep problems, such as insomnia, as a side effect.

Q: Does Dibazol-UBF affect liver function test results?

A: Official research has documented a temporary elevation in liver enzymes in some studies, which was reported to normalize upon cessation of the assessment. Regulatory documents state that caution is necessary for patients with documented severe hepatic impairment (severe liver issues).

Q: Is temporary hair loss a known side effect of the Dibazol-UBF drug class?

A: While not explicitly listed in all Bendazol product labels, some medicinal products that belong to the same benzimidazole chemical class have been associated with reversible hair loss in authoritative safety documents. This information pertains to the drug class of benzimidazoles, which share a common chemical structure with Bendazol.

Q: Are there any common over-the-counter pain relievers that interact with Dibazol-UBF?

A: Regulatory documents do not list specific interactions with common over-the-counter pain relievers outside of other blood pressure medications. Official texts also note that no interactions related to drug metabolism via CYP enzymes are explicitly documented for Bendazol.

Q: Does taking calcium or magnesium supplements affect how Dibazol-UBF works?

A: Official regulatory texts do not document specific interactions with herbal products or supplements, such as calcium or magnesium. The interaction profile is primarily focused on the additive effects when combined with other blood pressure-lowering agents.

Q: Is there a risk of interaction between Dibazol-UBF and alcohol?

A: Official safety notes indicate that consuming alcohol can exacerbate side effects of Dibazol-UBF. This combination increases the risk of effects such as dizziness and abnormally low blood pressure (hypotension).

Q: Are there any specific foods that should be avoided while taking Dibazol-UBF?

A: No. Official administration instructions do not specify a critical time relation to meals, such as 'with food' or 'on an empty stomach.' Furthermore, no specific food interactions are documented in the regulatory texts.

Q: Why is Dibazol-UBF widely used in some regions but less common in the US or Western Europe?

A: The difference in regional use may be related to the drug's origin as a synthetic compound from the former Soviet Union. Its unique dual classification as both an Antihypertensive and a non-specific Immunomodulator may also contribute to variations in official labeling and common usage globally.

Q: Is Dibazol-UBF chemically related to other benzimidazole drugs?

A: Yes, its active ingredient is Bendazol, which official documents classify as a Synthetic Benzimidazole Derivative. This chemical relationship links it to a broader group of drugs that share the same core molecular structure.

Q: Is Dibazol-UBF available over the counter, or is a prescription required?

A: Official classification documents list Dibazol-UBF as a Prescription only medicine. This means that a prescription from a licensed healthcare provider is necessary for dispensing.

Q: Is Dibazol-UBF used to treat high blood pressure only, or are there other main uses?

A: The drug is officially categorized within two primary pharmacological classes: an Antihypertensive Agent (for blood pressure reduction) and a Myotropic Antispasmodic agent (for smooth muscle relaxation). These two actions represent its main therapeutic uses.

Q: Can Dibazol-UBF be used for conditions outside of blood pressure and spasms?

A: Yes, the official classification includes a secondary role as an adaptogen and non-specific immunomodulator. This profile is supported by its recognized capacity to support the body's general resistance and non-specific defense mechanisms.

Q: What is the official information regarding Dibazol-UBF use during pregnancy?

A: Use during pregnancy is officially Contraindicated or Not Recommended in all trimesters. Official safety notes state that the safety profile for this population is not firmly established and the medication is intended for use only when the potential benefit is judged to outweigh the unknown risk.

Q: Is there an officially recognized maximum daily amount of Dibazol-UBF?

A: No universal dosage or fixed duration is specified by major global regulatory bodies. Official guidelines state that the precise labeled dosage and treatment cycles are specific to the local regulatory documentation in the country where it is used.

Q: Can people with kidney issues use Dibazol-UBF?

A: Regulatory documents indicate that caution and consideration are necessary for patients who have documented severe renal impairment (severe kidney issues). Caution is also advised for those with severe hepatic impairment (severe liver issues).

Q: Can individuals who have a history of severe heart disease or heart failure use Dibazol-UBF?

A: Regulatory documents indicate that caution and close monitoring are necessary for patients with pre-existing conditions like severe coronary artery disease or heart failure. This restriction is due to the drug's vasodilatory (blood vessel widening) action.

The official regulatory requirements for Dibazol-UBF (Bendazol) mandate strict storage conditions. The medicine must be kept at controlled room temperature, typically 20 C to 25 C. It is required to protect the product from light, excess moisture, and freezing. Keep the product in its original, tightly closed container until use.

Disposal Instructions

The medicine must be kept out of the sight and reach of children. Disposal of unused or expired Dibazol-UBF must adhere to official guidelines. The preferred method is to utilize a drug take-back program or an authorized collection site. If a take-back program is unavailable, follow the household disposal procedure: mix the product with an undesirable substance (e.g., dirt, cat litter) in a sealed bag, and discard it in the trash. Do not flush the medicine down the toilet or sink.